CLINICAL FORMS OF PRESENTATION AND EVOLUTION OF DIFFUSE SCLEROSING VARIANT OF PAPILLARY CARCINOMA AND INSULAR VARIANT OF FOLLICULAR CARCINOMA OF THE THYROID

Citation
M. Albareda et al., CLINICAL FORMS OF PRESENTATION AND EVOLUTION OF DIFFUSE SCLEROSING VARIANT OF PAPILLARY CARCINOMA AND INSULAR VARIANT OF FOLLICULAR CARCINOMA OF THE THYROID, Thyroid, 8(5), 1998, pp. 385-391
Citations number
17
Categorie Soggetti
Endocrynology & Metabolism
Journal title
ISSN journal
10507256
Volume
8
Issue
5
Year of publication
1998
Pages
385 - 391
Database
ISI
SICI code
1050-7256(1998)8:5<385:CFOPAE>2.0.ZU;2-9
Abstract
We investigated whether the diffuse sclerosing variant of papillary ca rcinoma (diffuse sclerosing PC) and insular carcinoma (IC), two differ ent subforms of differentiated carcinoma of the thyroid gland, have di fferent clinical behaviors and prognosis in order to select appropriat e therapy. The characteristics of clinical presentation, and outcome a fter therapy were evaluated in a series of 113 patients (18 males and 95 females) with differentiated thyroid carcinoma treated with the sam e protocol, of which 7 had diffuse sclerosing PC and 6 had IC; within this series, patients with diffuse sclerosing PC and IC were compared with 76 cases of papillary carcinoma (PC) and 24 cases of follicular c arcinoma (FC), respectively. Diffuse sclerosing PC patients were young er (23 +/- 9 vs. 38 +/- 16 years) and had a higher degree of lymphatic metastases at diagnosis (100%) than patients with PC (47%). Five of 7 patients with diffuse sclerosing PC were alive and without evidence o f disease compared to 34 of 76 patients with PC at follow-up (6.4 +/- 5.1 and 7.9 +/- 7 years, respectively). No prognostic differences were found between them. IC showed a more advanced stage of disease at dia gnosis and a more aggressive clinical course with a higher percent of metastases and mortality than patients with FC at follow-up (1 patient died and 5 were alive with persistent disease at 4.8 +/- 3.7 years fo r IC; 22 were alive, 13 of them with persistent disease; and 2 died at 8.4 +/- 5.3 years for FC). We conclude that patients with diffuse scl erosing PC do not require a different treatment than that given to PC patients, while in contrast, IC cases need a more aggressive therapeut ic approach.